Wells Fargo & Company MN Raises Stake in Evolus, Inc. (NASDAQ:EOLS)

Wells Fargo & Company MN increased its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 41.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 49,347 shares of the company’s stock after buying an additional 14,506 shares during the period. Wells Fargo & Company MN owned about 0.08% of Evolus worth $545,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. KBC Group NV purchased a new stake in shares of Evolus during the 4th quarter worth approximately $49,000. IFP Advisors Inc grew its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Evolus in the fourth quarter worth $106,000. Quantbot Technologies LP purchased a new stake in Evolus in the fourth quarter worth $118,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after buying an additional 1,291 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Stock Up 2.4 %

EOLS stock opened at $12.08 on Friday. The stock has a 50-day simple moving average of $11.98 and a two-hundred day simple moving average of $12.77. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The firm has a market capitalization of $768.13 million, a PE ratio of -13.27 and a beta of 0.97. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Insider Activity

In other news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares in the company, valued at approximately $6,306,875.60. This trade represents a 1.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rui Avelar sold 27,904 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the transaction, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,575 shares of company stock worth $794,369. 6.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. BTIG Research initiated coverage on Evolus in a report on Thursday, April 17th. They issued a “buy” rating and a $21.00 price objective for the company. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.